nach oben

Erschienen in:

01.09.2014 | Leitlinien

DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen

8.4 Medikamentöse Therapie, 8.5 Evaluation des Therapieerfolgs medikamentöser Maßnahmen

verfasst von: Dr. U. Kiltz, J. Sieper, H. Kellner, D. Krause, M. Rudwaleit, J.-F. Chenot, A. Stallmach, S. Jaresch, J. Braun

Erschienen in: Zeitschrift für Rheumatologie | Sonderheft 2/2014

Einloggen, um Zugang zu erhalten

Auszug

Schlüsselfrage 10: welche medikamentöse Therapie sollte zu welchem Zeitpunkt bei Patienten mit axialer SpA eingesetzt werden und für wie lange? …

Barkhuizen A et al (2006) Celecoxib is efficacious and well tolerated in treating signs and symptoms of ankylosing spondylitis. J Rheumatol 33(9):1805–1812PubMed

Dougados M et al (1989) A double blind crossover placebo controlled trial of ximoprofen in as. J Rheumatol 16(8):1167–1169PubMed

Dougados M et al (1994) Ximoprofen in ankylosing spondylitis. A double blind placebo controlled dose ranging study. Scand J Rheumatol 23(5):243–248PubMed

Sturrock RD, Hart FD (1974) Double-blind cross-over comparison of indomethacin, flurbiprofen, and placebo in ankylosing spondylitis. Ann Rheum Dis 33(2):129–131PubMedPubMedCentral

Heijde D van der et al (2005) Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study. Arthritis Rheum 52(4):1205–1215PubMed

Gossec L et al (2005) Efficacy of cyclo-oxygenase-2 inhibition by etoricoxib and naproxen on the axial manifestations of ankylosing spondylitis in the presence of peripheral arthritis. Ann Rheum Dis 64(11):1563–1567PubMedPubMedCentral

Sieper J et al (2008) Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study. Ann Rheum Dis 67(3):323–329PubMed

Escalas C, Trijau S, Dougados M (2010) Evaluation of the treatment effect of NSAIDs/TNF blockers according to different domains in ankylosing spondylitis: results of a meta-analysis. Rheumatology (Oxford) 49(7):1317–1325

Zochling J et al (2006) Nonsteroidal anti-inflammatory drug use in ankylosing spondylitis – a population-based survey. Clin Rheumatol 25(6):794–800PubMed

10.

Wanders A et al (2005) Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum 52(6):1756–1765PubMed

11.

Kroon F et al (2012) Continuous NSAID use reverts the effects of inflammation on radiographic progression in patients with ankylosing spondylitis. Ann Rheum Dis 71(10):1623–1629PubMed

12.

Poddubnyy D et al (2012) Effect of non-steroidal anti-inflammatory drugs on radiographic spinal progression in patients with axial spondyloarthritis: results from the German Spondyloarthritis Inception Cohort. Ann Rheum Dis 71(10):1616–1622PubMed

13.

Jarrett SJ et al (2009) MRI and clinical findings in patients with ankylosing spondylitis eligible for anti-tumour necrosis factor therapy after a short course of etoricoxib. Ann Rheum Dis 68(9):1466–1469PubMed

14.

Benhamou M, Gossec L, Dougados M (2010) Clinical relevance of C-reactive protein in ankylosing spondylitis and evaluation of the NSAIDs/coxibs‘ treatment effect on C-reactive protein. Rheumatology (Oxford) 49(3):536–541

15.

Peloso PM et al (2011) Longitudinal numbers-needed-to-treat (NNT) for achieving various levels of analgesic response and improvement with etoricoxib, naproxen, and placebo in ankylosing spondylitis. BMC Musculoskelet Disord 12:165PubMedPubMedCentral

16.

Heijde D van der et al (2011) 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 70(6):905–908PubMed

17.

Cannon CP et al (2006) Cardiovascular outcomes with etoricoxib and diclofenac in patients with osteoarthritis and rheumatoid arthritis in the Multinational Etoricoxib and Diclofenac Arthritis Long-term (MEDAL) programme: a randomised comparison. Lancet 368(9549):1771–1781PubMed

18.

Farkouh ME et al (2004) Comparison of lumiracoxib with naproxen and ibuprofen in the Therapeutic Arthritis Research and Gastrointestinal Event Trial (TARGET), cardiovascular outcomes: randomised controlled trial. Lancet 364(9435):675–684PubMed

19.

Song IH et al (2008) Benefits and risks of ankylosing spondylitis treatment with nonsteroidal antiinflammatory drugs. Arthritis Rheum 58(4):929–938PubMed

20.

Bolten W (2009) Nichtsteroidale Antirheumatika, aktualisierte Empfehlungen zur Verordnung. Deutsche Gesellschaft für Rheumatologie

21.

Burmester G et al (2011) The appropriate use of non-steroidal anti-inflammatory drugs in rheumatic disease: opinions of a multidisciplinary European expert panel. Ann Rheum Dis 70(5):818–822PubMedPubMedCentral

22.

Ärzteschaft, A.d.d. (2008) Empfehlungen zur Therapie von degenerativen Gelenkerkrankungen, Bd. 35, Sonderheft 1. A.d.d. Ärzteschaft

23.

Basavaraj KH et al (2010) The role of drugs in the induction and/or exacerbation of psoriasis. Int J Dermatol 49(12):1351–1361PubMed

24.

Braun J et al (2011) 2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 70(6):896–904PubMedPubMedCentral

25.

Braun J et al (1995) Use of immunohistologic and in situ hybridization techniques in the examination of sacroiliac joint biopsy specimens from patients with ankylosing spondylitis. Arthritis Rheum 38(4):499–505PubMed

26.

Zochling J et al (2006) Current evidence for the management of ankylosing spondylitis: a systematic literature review for the ASAS/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 65(4):423–432PubMedPubMedCentral

27.

Heijde D van der et al (2008) Adalimumab effectively reduces the signs and symptoms of active ankylosing spondylitis in patients with total spinal ankylosis. Ann Rheum Dis 67(9):1218–1221PubMedPubMedCentral

28.

Dougados M et al (2011) Efficacy of etanercept on rheumatic signs and pulmonary function tests in advanced ankylosing spondylitis: results of a randomised double-blind placebo-controlled study (SPINE). Ann Rheum Dis 70(5):799–804PubMedPubMedCentral

29.

Haibel H et al (2008) Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 58(7):1981–1991PubMed

30.

Song IH et al (2011) Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 70(4):590–596PubMedPubMedCentral

31.

Barkham N et al (2009) Clinical and imaging efficacy of infliximab in HLA-B27-Positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 60(4):946–954PubMed

32.

Sieper J et al (2012) Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo-controlled trial (ABILITY-1). Ann Rheum Dis

33.

Heijde D van der et al (2006) Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 54(7):2136–2146PubMed

34.

Heijde D van der et al (2009) Adalimumab effectiveness for the treatment of ankylosing spondylitis is maintained for up to 2 years: long-term results from the ATLAS trial. Ann Rheum Dis 68(6):922–929PubMedPubMedCentral

35.

Heijde DM van der et al (2009) Physical function, disease activity, and health-related quality-of-life outcomes after 3 years of adalimumab treatment in patients with ankylosing spondylitis. Arthritis Res Ther 11(4):R124PubMedPubMedCentral

36.

Davis JC Jr et al (2003) Recombinant human tumor necrosis factor receptor (etanercept) for treating ankylosing spondylitis: a randomized, controlled trial. Arthritis Rheum 48(11):3230–3236PubMed

37.

Davis JC et al (2005) Sustained durability and tolerability of etanercept in ankylosing spondylitis for 96 weeks. Ann Rheum Dis 64(11):1557–1562PubMedPubMedCentral

38.

Davis JC Jr et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67(3):346–352PubMed

39.

Calin A et al (2004) Outcomes of a multicentre randomised clinical trial of etanercept to treat ankylosing spondylitis. Ann Rheum Dis 63(12):1594–1600PubMedPubMedCentral

40.

Dijkmans B et al (2009) Etanercept in the longterm treatment of patients with ankylosing spondylitis. J Rheumatol 36(6):1256–1264PubMed

41.

Martin-Mola E et al (2010) Sustained efficacy and safety, including patient-reported outcomes, with etanercept treatment over 5 years in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(2):238–245PubMed

42.

Heijde D van der et al (2006) Etanercept 50 mg once weekly is as effective as 25 mg twice weekly in patients with ankylosing spondylitis. Ann Rheum Dis 65(12):1572–1577PubMedPubMedCentral

43.

Dougados M et al (2010) A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial. Ann Rheum Dis 69(8):1430–1435PubMed

44.

Navarro-Sarabia F et al (2011) High-dose etanercept in ankylosing spondylitis: results of a 12-week randomized, double blind, controlled multicentre study (LOADET study). Rheumatology (Oxford) 50(10):1828–1837

45.

Braun J et al (2011) Clinical efficacy and safety of etanercept versus sulfasalazine in patients with ankylosing spondylitis: a randomized, double-blind trial. Arthritis Rheum 63(6):1543–1551PubMed

46.

Inman RD et al (2008) Efficacy and safety of golimumab in patients with ankylosing spondylitis: results of a randomized, double-blind, placebo-controlled, phase III trial. Arthritis Rheum 58(11):3402–3412PubMed

47.

Braun J et al (2002) Treatment of active ankylosing spondylitis with infliximab: a randomised controlled multicentre trial. Lancet 359(9313):1187–1193PubMed

48.

Braun J et al (2005) Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis 64(2):229–234PubMedPubMedCentral

49.

Braun J et al (2005) Persistent clinical response to the anti-TNF-alpha antibody infliximab in patients with ankylosing spondylitis over 3 years. Rheumatology (Oxford) 44(5):670–676

50.

Braun J et al (2008) Persistent clinical efficacy and safety of anti-tumour necrosis factor alpha therapy with infliximab in patients with ankylosing spondylitis over 5 years: evidence for different types of response. Ann Rheum Dis 67(3):340–345PubMed

51.

Baraliakos X et al (2011) Persistent clinical efficacy and safety of infliximab in ankylosing spondylitis after 8 years – early clinical response predicts long-term outcome. Rheumatology (Oxford) 50(9):1690–1699

52.

Heijde D van der et al (2005) Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT). Arthritis Rheum 52(2):582–591PubMed

53.

Heldmann F et al (2011) The European ankylosing spondylitis infliximab cohort (EASIC): a European multicentre study of long term outcomes in patients with ankylosing spondylitis treated with infliximab. Clin Exp Rheumatol 29(4):672–680PubMed

54.

Revicki DA et al (2008) Adalimumab reduces pain, fatigue, and stiffness in patients with ankylosing spondylitis: results from the adalimumab trial evaluating long-term safety and efficacy for ankylosing spondylitis (ATLAS). J Rheumatol 35(7):1346–1353PubMed

55.

Kristensen LE et al (2010) Presence of peripheral arthritis and male sex predicting continuation of anti-tumor necrosis factor therapy in ankylosing spondylitis: an observational prospective cohort study from the South Swedish Arthritis Treatment Group Register. Arthritis Care Res (Hoboken) 62(10):1362–1369

56.

Sieper J et al (2010) Analysis of uveitis rates across all etanercept ankylosing spondylitis clinical trials. Ann Rheum Dis 69(1):226–229PubMed

57.

Braun J et al (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447–2451PubMed

58.

Braun J et al (2007) Differences in the incidence of flares or new onset of inflammatory bowel diseases in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 57(4):639–647PubMed

59.

Cohen JD et al (2007) Psoriasis induced by tumor necrosis factor-alpha antagonist therapy: a case series. J Rheumatol 34(2):380–385PubMed

60.

Vries MK de et al (2009) Erythrocyte sedimentation rate, C-reactive protein level, and serum amyloid a protein for patient selection and monitoring of anti-tumor necrosis factor treatment in ankylosing spondylitis. Arthritis Rheum 61(11):1484–1490PubMed

61.

Braun J et al (2009) Improvement in hemoglobin levels in patients with ankylosing spondylitis treated with infliximab. Arthritis Rheum 61(8):1032–1036PubMed

62.

Gonnet-Gracia C et al (2008) Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers. Clin Exp Rheumatol 26(3):401–407PubMed

63.

Baraliakos X et al (2005) Magnetic resonance imaging examinations of the spine in patients with ankylosing spondylitis before and after therapy with the tumor necrosis factor alpha receptor fusion protein etanercept. Arthritis Rheum 52(4):1216–1223PubMed

64.

Braun J et al (2006) Major reduction in spinal inflammation in patients with ankylosing spondylitis after treatment with infliximab: results of a multicenter, randomized, double-blind, placebo-controlled magnetic resonance imaging study. Arthritis Rheum 54(5):1646–1652PubMed

65.

Maksymowych WP et al (2010) Low-dose infliximab (3 mg/kg) significantly reduces spinal inflammation on magnetic resonance imaging in patients with ankylosing spondylitis: a randomized placebo-controlled study. J Rheumatol 37(8):1728–1734PubMed

66.

Heijde D van der et al (2008) Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 58(5):1324–1331PubMed

67.

Baraliakos X et al (2007) Radiographic progression in patients with ankylosing spondylitis after 4 yrs of treatment with the anti-TNF-alpha antibody infliximab. Rheumatology (Oxford) 46(9):1450–1453

68.

Visvanathan S et al (2009) Effects of infliximab on markers of inflammation and bone turnover and associations with bone mineral density in patients with ankylosing spondylitis. Ann Rheum Dis 68(2):175–182PubMedPubMedCentral

69.

Davis JC Jr et al (2007) Health-related quality of life outcomes in patients with active ankylosing spondylitis treated with adalimumab: results from a randomized controlled study. Arthritis Rheum 57(6):1050–1057PubMed

70.

Braun J et al (2007) Improvement in patient-reported outcomes for patients with ankylosing spondylitis treated with etanercept 50 mg once-weekly and 25 mg twice-weekly. Rheumatology (Oxford) 46(6):999–1004

71.

Boonen A et al (2008) Rapid and sustained improvement in health-related quality of life and utility for 72 weeks in patients with ankylosing spondylitis receiving etanercept. J Rheumatol 35(4):662–667PubMed

72.

Kimel M et al (2011) Norms-based assessment of patient-reported outcomes associated with adalimumab monotherapy in patients with ankylosing spondylitis. Clin Exp Rheumatol 29(4):624–632PubMed

73.

Verstappen SM et al (2011) Anti-TNF therapies and pregnancy: outcome of 130 pregnancies in the British Society for Rheumatology Biologics Register. Ann Rheum Dis 70(5):823–826PubMedPubMedCentral

74.

Villiger PM et al (2010) Effects of TNF antagonists on sperm characteristics in patients with spondyloarthritis. Ann Rheum Dis 69(10):1842–1844PubMed

75.

Heijde D van der et al (2006) Infliximab improves productivity and reduces workday loss in patients with ankylosing spondylitis: results from a randomized, placebo-controlled trial. Arthritis Rheum 55(4):569–574PubMed

76.

Barkham N et al (2010) Double-blind placebo-controlled trial of etanercept in the prevention of work disability in ankylosing spondylitis. Ann Rheum Dis 69(11):1926–1928PubMed

77.

Keat AC et al (2008) Influence of biologic therapy on return to work in people with work disability due to ankylosing spondylitis. Rheumatology (Oxford) 47(4):481–483

78.

Kristensen LE et al (2011) Sick leave in patients with ankylosing spondylitis before and after anti-TNF therapy: a population-based cohort study. Rheumatology (Oxford)

79.

Maksymowych WP et al (2010) Impact of age, sex, physical function, health-related quality of life, and treatment with adalimumab on work status and work productivity of patients with ankylosing spondylitis. J Rheumatol 37(2):385–392PubMed

80.

Braun J et al (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62(9):817–824PubMedPubMedCentral

81.

Braun J et al (2006) First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 65(3):316–320PubMedPubMedCentral

82.

Kiltz U, Sieper J, Braun J (2013) ASAS recommendations on the use of TNF inhibitors for patients with axial spondyloarthritis: evaluation of the 2010 update in the German-speaking area. Z Rheumatol 72(1):81–88PubMed

83.

Heijde D van der et al (1997) Preliminary core sets for endpoints in ankylosing spondylitis. Assessments in Ankylosing Spondylitis Working Group. J Rheumatol 24(11):2225–2229PubMed

84.

Heiberg MS et al (2008) The comparative one-year performance of anti-tumor necrosis factor alpha drugs in patients with rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: results from a longitudinal, observational, multicenter study. Arthritis Rheum 59(2):234–240PubMed

85.

Arends S et al (2011) Baseline predictors of response and discontinuation of tumor necrosis factor-alpha blocking therapy in ankylosing spondylitis: a prospective longitudinal observational cohort study. Arthritis Res Ther 13(3):R94PubMedPubMedCentral

86.

Vastesaeger N et al (2011) Predicting the outcome of ankylosing spondylitis therapy. Ann Rheum Dis 70(6):973–981PubMedPubMedCentral

87.

Glintborg B et al (2010) Predictors of treatment response and drug continuation in 842 patients with ankylosing spondylitis treated with anti-tumour necrosis factor: results from 8 years‘ surveillance in the Danish nationwide DANBIO registry. Ann Rheum Dis 69(11):2002–2008PubMed

88.

Lord PA et al (2010) Predictors of response to anti-TNF therapy in ankylosing spondylitis: results from the British Society for Rheumatology Biologics Register. Rheumatology (Oxford) 49(3):563–570

89.

Sieper J et al (2012) Early response to adalimumab predicts long-term remission through 5 years of treatment in patients with ankylosing spondylitis. Ann Rheum Dis 71(5):700–706PubMedPubMedCentral

90.

Breban M et al (2008) Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum 58(1):88–97PubMed

91.

Marzo-Ortega H et al (2005) Infliximab in combination with methotrexate in active ankylosing spondylitis: a clinical and imaging study. Ann Rheum Dis 64(11):1568–1575PubMedPubMedCentral

92.

Li EK et al (2008) Short-term efficacy of combination methotrexate and infliximab in patients with ankylosing spondylitis: a clinical and magnetic resonance imaging correlation. Rheumatology (Oxford) 47(9):1358–1363

93.

Perez-Guijo VC et al (2007) Increased efficacy of infliximab associated with methotrexate in ankylosing spondylitis. Joint Bone Spine 74(3):254–258PubMed

94.

Giardina AR et al (2010) A 2-year comparative open label randomized study of efficacy and safety of etanercept and infliximab in patients with ankylosing spondylitis. Rheumatol Int 30(11):1437–1440PubMed

95.

Braun J et al (2011) Golimumab administered subcutaneously every 4 weeks in ankylosing spondylitis: 104-week results of the GO-RAISE study. Ann Rheum Dis

96.

Braun J et al (2011) Golimumab reduces spinal inflammation in ankylosing spondylitis: MRI results of the randomised, placebo- controlled GO-RAISE study. Ann Rheum Dis

97.

Baraliakos X et al (2005) Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab. Arthritis Res Ther 7(3):R439–R444PubMedPubMedCentral

98.

Inman RD, Maksymowych WP (2010) A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol 37(6):1203–1210PubMed

99.

Krzysiek R et al (2009) Circulating concentration of infliximab and response to treatment in ankylosing spondylitis: results from a randomized control study. Arthritis Rheum 61(5):569–576PubMed

100.

Arends S et al (2010) The formation of autoantibodies and antibodies to TNF-alpha blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28(5):661–668PubMed

101.

Vries MK de et al (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti-infliximab formation. Ann Rheum Dis 66(9):1252–1254PubMedPubMedCentral

102.

Bartelds GM et al (2010) Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study. Ann Rheum Dis 69(5):817–821PubMed

103.

Vries MK de et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68(4):531–535PubMed

104.

Lie E et al (2011) Effectiveness of switching between TNF inhibitors in ankylosing spondylitis: data from the NOR-DMARD register. Ann Rheum Dis 70(1):157–163PubMed

105.

Rudwaleit M et al (2010) Effectiveness and safety of adalimumab in patients with ankylosing spondylitis or psoriatic arthritis and history of anti-tumor necrosis factor therapy. Arthritis Res Ther 12(3):R117PubMedPubMedCentral

106.

Diel R et al (2009) Recommendations for tuberculosis screening before initiation of TNF-alpha-inhibitor treatment in rheumatic diseases. Pneumologie 63(6):329–334PubMed

107.

Fouque-Aubert A et al (2010) Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebo-controlled trials. Ann Rheum Dis 69(10):1756–1761PubMed

108.

Mariette X et al (2011) Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis. Ann Rheum Dis 70(11):1895–1904PubMed

109.

Pham T et al (2011) TNF alpha antagonist therapy and safety monitoring. Joint Bone Spine 78(Suppl 1):15–185PubMed

110.

Song IH et al (2010) Different response to rituximab in tumor necrosis factor blocker-naive patients with active ankylosing spondylitis and in patients in whom tumor necrosis factor blockers have failed: a twenty-four-week clinical trial. Arthritis Rheum 62(5):1290–1297PubMed

111.

Song IH et al (2011) Treatment of active ankylosing spondylitis with abatacept: an open-label, 24-week pilot study. Ann Rheum Dis 70(6):1108–1110PubMed

112.

Chen J, Liu C (2005) Sulfasalazine for ankylosing spondylitis. Cochrane Database Syst Rev 2:CD004800PubMed

113.

Genc H et al (2007) The effects of sulfasalazine treatment on enthesal abnormalities of inflammatory rheumatic diseases. Clin Rheumatol 26(7):1104–1110PubMed

114.

Braun J et al (2006) Efficacy of sulfasalazine in patients with inflammatory back pain due to undifferentiated spondyloarthritis and early ankylosing spondylitis: a multicentre randomised controlled trial. Ann Rheum Dis 65(9):1147–1153PubMedPubMedCentral

115.

Benitez-Del-Castillo JM et al (2000) Sulfasalazine in the prevention of anterior uveitis associated with ankylosing spondylitis. Eye (Lond) 14 (Pt 3A):340–343

116.

Hoffmann JC et al (2008) Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 46(9):1094–1146PubMed

117.

Chen J, Liu C, Lin J (2006) Methotrexate for ankylosing spondylitis. Cochrane Database Syst Rev 4:CD004524PubMed

118.

Maksymowych WP et al (2002) A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug-refractory ankylosing spondylitis. Arthritis Rheum 46(3):766–773PubMed

119.

Haibel H et al (2003) Treatment of active ankylosing spondylitis with pamidronate. Rheumatology (Oxford) 42(8):1018–1020

120.

Cairns AP et al (2005) An open study of pulse pamidronate treatment in severe ankylosing spondylitis, and its effect on biochemical markers of bone turnover. Ann Rheum Dis 64(2):338–339PubMedPubMedCentral

121.

Malaviya AN et al (2007) A new strategy of drug treatment in NSAID-unresponsive ankylosing spondylitis: combination of pamidronate and methylprednisolone monthly intravenous infusions on the background of a combination of disease modifying drugs sulfasalazine and methotrexate. J Assoc Physicians India 55:193–197PubMed

122.

Santra G et al (2010) Assessment of the efficacy of pamidronate in ankylosing spondylitis: an open prospective trial. Singapore Med J 51(11):883–887PubMed

123.

Chatfield SM et al (2009) Complementary and alternative medicines in ankylosing spondylitis: a cross-sectional study. Clin Rheumatol 28(2):213–217PubMed

124.

Brophy S et al (2008) Internet-based randomised controlled trials for the evaluation of complementary and alternative medicines: probiotics in spondyloarthropathy. BMC Musculoskelet Disord 9:4PubMedPubMedCentral

125.

Jenks K et al (2010) Probiotic therapy for the treatment of spondyloarthritis: a randomized controlled trial. J Rheumatol 37(10):2118–2125PubMed

126.

Heijde D van der et al (2009) Assessment of radiographic progression in the spines of patients with ankylosing spondylitis treated with adalimumab for up to 2 years. Arthritis Res Ther 11(4):R127PubMedPubMedCentral

127.

Han C et al (2007) The impact of infliximab treatment on quality of life in patients with inflammatory rheumatic diseases. Arthritis Res Ther 9(5):R103PubMedPubMedCentral

128.

Visvanathan S et al (2008) Inflammatory biomarkers, disease activity and spinal disease measures in patients with ankylosing spondylitis after treatment with infliximab. Ann Rheum Dis 67(4):511–517PubMedPubMedCentral

Titel: DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen
8.4 Medikamentöse Therapie, 8.5 Evaluation des Therapieerfolgs medikamentöser Maßnahmen
verfasst von: Dr. U. Kiltz
J. Sieper
H. Kellner
D. Krause
M. Rudwaleit
J.-F. Chenot
A. Stallmach
S. Jaresch
J. Braun
Publikationsdatum: 01.09.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Zeitschrift für Rheumatologie / Ausgabe Sonderheft 2/2014
Print ISSN: 0340-1855
Elektronische ISSN: 1435-1250
DOI: https://doi.org/10.1007/s00393-014-1443-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

25.04.2024 | Hypotonie | Nachrichten

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

DGRh-S3-Leitlinie Axiale Spondyloarthritis inklusive Morbus Bechterew und Frühformen

8.4 Medikamentöse Therapie, 8.5 Evaluation des Therapieerfolgs medikamentöser Maßnahmen

Auszug

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

Viel Bewegung in der Parkinsonforschung

Adjuvante Immuntherapie verlängert Leben bei RCC

Update Innere Medizin

Springer Medizin

Auszug

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2014